objectively, no but sentiment is a powerful driver in the short-medium term. A UK sale coming off the back of the NZ sale and Swiss approval would suggest the company is gaining momentum and beginning to deliver. I think the market discounts this stock because of past failures. A UK sale may be enough for the market to remove the discount.
I note your point about cases and theoretical demand. I guess that’s good and bad. Either way, it’s a critical qtr.
Ann: OncoSil receives Swiss regulatory approval, page-10
-
- There are more pages in this discussion • 52 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add OSL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
1.2¢ |
Change
0.000(0.00%) |
Mkt cap ! $45.40M | |||
| Open | High | Low | Value | Volume |
| 1.1¢ | 1.2¢ | 1.1¢ | $50.21K | 4.210M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 15 | 7425926 | 1.1¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 1.2¢ | 2122533 | 4 |
View Market Depth
| Last trade - 16.10pm 19/08/2024 (20 minute delay) ? |
| OSL (ASX) Chart |